文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹皮肤肿瘤

免疫检查点抑制剂诱导的皮肤毒性的临床关联与分类:欧洲皮肤病与性病学会癌症患者皮肤病学工作组的一项多中心研究

Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
PubMed 文献 · Br J Dermatol · 2022-09-06

这项多中心回顾性国际队列研究纳入762例接受免疫检查点抑制剂(ICI)治疗后发生皮肤免疫相关不良事件(irAEs)的癌症患者,共发生993次皮肤毒性。银屑病(175例,23.0%)和瘙痒(171例,22.4%)最常见,其次为斑丘疹(161例,21.1%)和湿疹样反应(150例,19.7%)。多因素分析显示皮肤毒性与具体药物及基础肿瘤相关。

要点

  • 银屑病(23.0%)和瘙痒(22.4%)是ICI治疗中最常见的皮肤毒性。
  • 斑丘疹、白癜风或多发皮肤毒性患者中,因黑色素瘤接受ICI者多于非小细胞肺癌。
  • 斑丘疹和白癜风患者接受抗CTLA4治疗少于抗PD-1治疗(OR分别为0.11和0.07)。

核心结论

  • 皮肤导向的毒性并非单一模式,与具体药物和基础肿瘤等多种因素相关。
  • 应个体化制定随访计划以最小化可能影响最佳治疗结局的严重反应风险。

研究设计与样本

  • 多中心回顾性国际队列研究,纳入762例接受ICI治疗后发生皮肤irAEs的癌症患者。

主要发现

  • 共识别40种皮肤毒性,银屑病175例(23.0%)、瘙痒171例(22.4%)、斑丘疹161例(21.1%)、湿疹样反应150例(19.7%)。
  • 斑丘疹、白癜风或多发皮肤毒性患者中,因黑色素瘤接受ICI者多于非小细胞肺癌。
  • 斑丘疹患者中抗CTLA4治疗少于抗PD-1治疗(OR 0.11,95%CI 0.01-0.76);白癜风患者中抗CTLA4治疗少于抗PD-1治疗(OR 0.07,95%CI 0.006-0.78)。
  • 与瘙痒性皮疹相比,ICI联合化疗较ICI单药治疗患者较少发生银屑病(OR 0.08,95%CI 0.02-0.31)、苔藓样反应(OR 0.15,95%CI 0.03-0.77)和湿疹样反应(OR 0.24,95%CI 0.07-0.78)。

临床怎么用

  • 作者认为应提倡临床认识和专科皮肤科会诊。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cutaneous immune-related adverse events (irAEs) represent the most frequent toxicities induced by immune checkpoint inhibitors (ICIs). OBJECTIVES: To investigate clinical associations of cutaneous toxicities induced by different ICI therapies. METHODS: This was a multicentre retrospective international cohort study of patients with cancer who developed cutaneous irAEs under ICI therapy. Analysis was performed of the rates and basic characteristics of all cutaneous toxicities, and identification of any associations was performed using univariate and multivariate models. RESULTS: In total, 762 patients were included, who developed 993 cutaneous toxicities. Forty different types of skin toxicities were identified. Psoriasis (175 patients, 23·0%) and pruritus (171 patients, 22·4%) were the most common toxicities, followed by macular rash (161 patients, 21·1%) and eczematous-type reactions (150 patients, 19·7%). Multivariate analysis showed that among patients with macular rash, vitiligo or multiple toxicities, patients received ICIs more frequently for melanoma than for NSCLC. Moreover, anti-CTLA4 was less frequent than anti-programmed death 1 treatment in patients with macular rash [odds ratio (OR) 0·11, 95% confidence interval (CI) 0·01-0·76] and vitiligo (OR 0·07, 95% CI 0·006-0·78). A significant association was also seen in patients treated with a combination of ICI and chemotherapy vs. ICI monotherapy. They less frequently developed psoriasis (OR 0·08, 95% CI 0·02-0·31), lichenoid reactions (OR 0·15, 95% CI 0·03-0·77) and eczematous reactions (OR 0·24, 95% CI 0·07-0·78), all compared with pruritic rash. CONCLUSIONS: Our study showed that skin-oriented toxicities do not share a single pattern and are related to several factors, including the specific agent administered and the underlying malignancy treated. Follow-up plans should be individualized in order to minimize the risk for severe reactions that could compromise optimum therapeutic outcome. What is already known about this topic? Patients with cancer treated with different immune checkpoint inhibitors (ICIs) carry an increased risk of developing various types of skin toxicities. What are the clinical implications of this work? In this multicentre cohort study we showed that ICI-related skin toxicities do not share a single pattern and may depend on several factors, including the specific agent administered and the underlying malignancy. Among patients with macular rash, vitiligo or multiple skin toxicities, patients received ICIs more frequently for melanoma than for non-small cell lung cancer. The combination of ICI and chemotherapy compared with ICI monotherapy occurred to a lesser extent in patients with psoriatic rash lichenoid and eczematous reactions, compared with patients with pruritus. Clinical awareness and specialized dermatological consultation should be advocated.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Nikolaou VA, Apalla Z, Carrera C, et al. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients. Br J Dermatol. 2022. PMID: 35861701. doi:10.1111/bjd.21781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。